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Fatty Liver, Insulin Resistance,
and Features of Metabolic Syndrome
Relationships with coronary artery calcium in 10,153 people
KI-CHUL SUNG, MD, PHD1
SARAH H. WILD, MB BCHIR, PHD2
HYON JOO KWAG, MD, PHD3
CHRISTOPHER D. BYRNE, MB BCH, PHD4
OBJECTIVEdNonalcoholic fatty liver disease (NAFLD) coexists with insulin resistance (IR),
but it is uncertain whether NAFLD and IR contribute independently to atherosclerosis.We tested
whether fatty liver, IR, and metabolic syndrome (MetS) features (waist, glucose, triglyceride,
HDL cholesterol [HDL-C], and blood pressure) were associated with a marker of atherosclerosis
(coronary artery calcium [CAC] score .0), independently of cardiovascular risk factors and
cardiovascular disease (CVD).
RESEARCH DESIGN AND METHODSdData were analyzed from a South Korean
occupational cohort of 10,153 people who all received ultrasound measurements of fatty liver
and a cardiac computed tomography CAC score. IR was deﬁned by homeostasis model assess-
ment of IR (HOMA-IR)$75th percentile. Odds ratios (ORs) (95%CIs) for the presence of a CAC
score .0 were estimated using logistic regression.
RESULTSdThere were 915 people with a CAC score.0. MetS features were increased (glu-
cose, blood pressure, triglyceride, and waist) or decreased (HDL-C) among people with a CAC
score.0 (all comparisons against CAC score#0; P, 0.0001). Of subjects with a CAC score.0,
55% had fatty liver and 33.7% were insulin resistant. Fatty liver (OR 1.21 [95% CI 1.01–1.45];
P = 0.04) and HOMA-IR (1.10 [1.02–1.18]; P = 0.02) were associated with CAC score .0,
independently of all MetS features, conventional cardiovascular risk factors, and prior evidence
of CVD. The presence of IR and fatty liver combined was associated with CAC score .0 (1.53
[1.20–1.95]; P = 0.001).
CONCLUSIONSdFatty liver and HOMA-IR are both associated with a CAC score .0 (inde-
pendently of each other), features ofMetS, conventional cardiovascular risk factors, and existingCVD.
Diabetes Care 35:2359–2364, 2012
N onalcoholic fatty liver disease(NAFLD) often coexists with type2 diabetes and insulin resistance
(IR) but each factor may occur in the
absence of the other factors. Several pro-
spective studies have reported an
increased incidence of cardiovascular
events in people with NAFLD (1–12),
but it is still unclear whether NAFLD is
simply a risk marker that coexists with
other recognized cardiovascular disease
(CVD) risk factors, such as type 2 diabetes
and central obesity, that are associated
with IR or whether it is an independent
cardiovascular risk factor (13,14). IR has
been shown to be associated with coro-
nary artery calcium (CAC) (15) as a
marker of early atherosclerosis, but in
this study, IR was not associated with
CAC, after adjustment for metabolic syn-
drome (MetS) features, and the presence
of NAFLD was not described in this
cohort.
NAFLD is now recognized as a very
common condition in people with type 2
diabetes and, if it were proven that
NAFLD is an independent CVD risk factor,
independently of type 2 diabetes and IR, a
diagnosis of NAFLD could be used to
identify subgroups of individuals who
would receive particular beneﬁt from
intensive lifestyle modiﬁcation and phar-
macological treatment to decrease CVD risk
(16,17). Moreover future treatments for
NAFLDwouldneed to test whether treating
fatty liver speciﬁcally affects risk of CVD.
CAC scoring with cardiac computed
tomography (CT) is a sensitive method to
demonstrate the presence of early athero-
sclerosis, and the use of CAC scores may
improve CV risk prediction in asymptom-
atic individuals (18). Thus, estimation of
the CAC score provides a useful, noninva-
sive tool to investigate relationships
between NAFLD, IR, and development of
early coronary artery atherosclerosis in
order to better understand the relationship
between NAFLD, IR, and atherosclerosis.
Using data from a retrospective
cohort study with measurements of fatty
liver and CAC score, together with mea-
surement of BMI, waist circumference,
features of MetS, IR, conventional cardio-
vascular risk factors, and diabetes status
in all subjects, we have investigated the
relationship between fatty liver, IR, and a
CAC score.0.We tested whether 1) fatty
liver, IR, and conventional, easily mea-
sured features of MetS (waist, glucose, tri-
glyceride, HDL cholesterol [HDL-C], and
blood pressure) were associated with a
CAC score .0 (as a marker of the pres-
ence of early atherosclerosis) and 2) any
relationships were independent of con-
ventional cardiovascular risk factors and
existing vascular disease.
RESEARCH DESIGN AND
METHODSdThe study population
consisted of individuals who had a com-
prehensive health examination in 2010 at
Kangbuk Samsung Hospital. In South
Korea, employees are required to partici-
pate in annual or biennial health examina-
tions by the Industrial Safety and Health
Law. Some subjects voluntarily pay for
these health checks, and in other instances,
the individual’s employer pays for the
health check. Health checks include blood
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tests, anthropometry, and abdominal ultra-
sound examination, and, in some cases, the
health check can include CAC scoring by
CT. The CAC test is offered as part of the
health check program and therefore there is
no medical indication for performing the
test. MetS (deﬁned by the 2009 joint in-
terim statement of the International Diabe-
tes FederationTask Force onEpidemiology
and Prevention criteria, with waist circum-
ference thresholds that are speciﬁc for
Asian populations, $90 cm for men and
$80 cm for women) (19). Initially 14,976
participants underwent coronary CT scan-
ning to establish a CAC score, and individ-
uals were excluded from the current
analyses if data were missing for the fol-
lowing variables: alcohol consumption
(n = 151), smoking (n = 178), exercise
(n = 146), BMI (n = 41), waist circumfer-
ence (n = 42), hepatitis B surface antigen
(HBsAg) (n = 132), and hepatitis C virus
(HCV) Ab (n = 133). Individuals were also
excluded if HBsAg testing was positive
(n = 571), HCV Ab testing was positive
(n = 34), or daily alcohol intake was .20
g. Data from 10,153 participants were an-
alyzed. The study was approved by the
institutional review board at Kangbuk
Samsung Hospital, and the need for spe-
ciﬁc informed consent was waived by the
review board because personal identifying
information was not accessed.
Measurements and calculations
The health examination included a col-
lection of full medical histories, physical
examinations, and blood samples. Waist
circumference was measured according
to a standardized operating procedure. In
brief, in the midaxilliary line, the mid-
point between the lowest rib and the
superior iliac crest was identiﬁed. At this
point, a measuring tape (SECA 200,
circumference measuring tape) was
placed around the abdomen, ensuring
that the tape was horizontal to the ﬂoor.
A measurement was taken to the nearest
0.1 cm, at the end of a normal expiration.
If the two readings varied by .1%, there
was a computer-generated prompt to
take a third reading. BMI was calculated
as weight in kilograms divided by height
in meters squared. Questionnaires were
used to ascertain information regarding
alcohol consumption (g/day), smoking
(never, ex, current), and frequency of
moderate activity each week. Moderate
activity was deﬁned as .30 min activity
per day that induced slight breathless-
ness. The homeostasis model assessment
of IR (HOMA-IR) index was calculated by
the following equation: HOMA-IR = (fast-
ing insulin [mIU/mL] 3 fasting glucose
[mmol/L])/22.5. Since there are no
population-speciﬁc thresholds to indicate
IR in a Korean population, we stratiﬁed the
populations using the 75th percentile to
establish an IR group (HOMA-IR $75th
percentile = IR), as described previously
in this population (20); the European
Group for the Study of Insulin Resistance
has previously recommended that the top
quartile of fasting insulin concentrations be
used to deﬁne an insulin-resistant group in
normal populations (21).
Blood samples for laboratory tests
were collected after an overnight fast.
Fasting plasma glucose, total cholesterol,
triglyceride, LDL cholesterol (LDL-C),
and HDL-C concentrations were mea-
sured using Bayer Reagent Packs on an
automated chemistry analyzer (Advia
1650 Autoanalyzer; Bayer Diagnostics,
Leverkusen, Germany). Abdominal ultra-
sonography (Logic Q700MR; GEHealth-
care, Milwaukee, WI) was performed in
all subjects by experienced clinical radi-
ologists, and fatty liver was diagnosed
based on known standard criteria, in-
cluding hepatorenal echo contrast, liver
brightness, and vascular blurring using a
3.5-MHz probe (22).
CT scans were performed with a 64-
slice MDCT scanner (Lightspeed VCT
XTe-64 slice; GE Healthcare), and a stan-
dard scanning protocol was 32 3 0.625-
mm section collimation, 400-ms rotation
time, 120-kV tube voltage, and 31-mAS
(310mA3 0.1 s) tube current under elec-
trocardiographic-gated dose modulation.
The quantitative CAC score was calcu-
lated according to the method described
by Agatston et al. (23). The presence of
CAC was deﬁned by a CAC score .0.
Statistical analysis
Statistical analysis of the data was per-
formed using SPSS version 15.0 (SPSS,
Point Richmond, CA). Continuous varia-
bles were expressed as mean 6 SD for
normally distributed variables or median
(interquartile range) if not normally dis-
tributed. Comparisons between groups
with CAC score = 0 and .0 were under-
taken both with and without stratiﬁcation
by sex and quartiles of waist circumference.
Categorical variables were expressed as
percentages and compared between groups
using the x2 test. We used logistic regres-
sion analysis to determine the odds ratio
(OR) of presence of coronary calcium asso-
ciated with fatty liver, HOMA-IR (as a con-
tinuous variable), and IR (as a categorical
variable, deﬁned by identifying people in
the top quartile of HOMA-IR).
Adjustments were also made for the
following variables: age, sex, smoking
status (never, ex, or current), frequency
of moderate activity per week, alcohol
consumption (units/day), and past his-
tory of cerebrovascular accident (CVA),
coronary heart disease (CHD), diabetes,
and hypertension diagnosed by question-
naire. P values ,0.05 were considered to
be statistically signiﬁcant.
The association (OR 6 95% CIs)
between fatty liver and CAC .0 score
was investigated in various subgroups
(men vs. women; younger vs. older ac-
cording to median age [#41 vs. .41
years]; low vs. high waist circumference
[waist circumference thresholds of
,/$90 cm for men, and ,/$80 cm for
women]; no MetS vs. MetS; and not in-
sulin resistant vs. insulin resistant) in
multivariable regression analyses.
RESULTSdTable 1 shows the charac-
teristics of the 915 people who had a CAC
score .0 compared with those with a
CAC score = 0. The proportion of people
with fatty liver, diabetes, and MetS was
higher in people with a CAC score .0.
Levels of components of MetS (24) (glu-
cose, blood pressure, triglyceride, and
waist circumference) were higher, or
lower (HDL-C), in people with a CAC
score.0. HOMA-IR, and the proportion
of people with IR, was increased in people
with a CAC score .0.
The results of multivariable regres-
sion models including all risk factors with
CAC score.0 as the outcome are shown
in Table 2. Diabetes, HOMA-IR (as a con-
tinuous variable), and fatty liver were all
independently associated with CAC score
.0 in addition to older age, smoking,
increased LDL-C concentrations, and
male sex. For MetS variables, triglyceride
was not associated with CAC score .0,
whereas signiﬁcant associations were
observed with HDL-C and systolic blood
pressure, and there was a borderline sig-
niﬁcant association observed with waist
circumference (P = 0.06).
Since fatty liver is strongly associated
with IR, we identiﬁed people in the top
quartile of HOMA-IR ($1.75) to establish
an IR group. The prevalence of CAC score
.0 in four groups, 1) people with neither
fatty liver nor IR, 2) people with fatty liver
alone, 3) people with IR alone, and 4)
people with both fatty liver and IR, is
described in Table 3, which also demon-
strates the prevalence of the combination of
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risk factors. Of all people with fatty liver,
44% were in the top quartile of HOMA-IR,
and 74% of people in the top quartile of
HOMA-IR had fatty liver.
To test the association between IR and
CAC score .0, we repeated the regres-
sion model shown in Table 2, replacing
HOMA-IR (as a continuous variable) with
IR as a categorical variable deﬁned as
above. In this regression model, the rela-
tionships between both fatty liver and IR
with CAC score .0 were similar com-
pared with the data in Table 2: fatty liver,
OR 1.20 (95% CI 1.00–1.44), P = 0.049;
IR, 1.29 (1.07–1.55), P = 0.009. When
fatty liver and HOMA-IR were omitted
from this regression model, the goodness
of ﬁt of the multivariable model was im-
proved signiﬁcantly by the addition of
fatty liver alone (x2 = 5.9 on one degree
of freedom; P = 0.015), IR alone (x2 = 7.4
on one degree of freedom; P = 0.007), or
both fatty liver and IR together (x2 = 11.7
on two degrees of freedom; P = 0.009).
We further investigated the associa-
tion between fatty liver and CAC .0
score in various subgroups (men vs.
women; younger vs. older; low vs. high
waist circumference; no MetS vs. MetS;
and not insulin resistant vs. insulin resis-
tant) (Fig. 1). There was no evidence of
marked heterogeneity between strata, but
there was limited power to detect interac-
tions. However, there was a suggestion
that the association between fatty liver
and CAC .0 score may be stronger in
women than men and in people without
IR or MetS.
In a further regression model, we
investigated the effect of fatty liver alone,
IR alone, and fatty liver and IR combined,
including these groups and all other risk
factors described in Table 3, in order to
test the effect of combining fatty liver and
IR on the OR for the association with CAC
score.0. Fatty liver alone (OR 1.26 [95%
CI 1.03–1.54]; P = 0.021) and IR alone
(1.50 [1.09–2.08]; P = 0.013) were inde-
pendently associated with CAC score.0.
Importantly, the combination of fatty
liver and IR showed a similar association
with CAC score .0 (1.53 [1.20–1.95];
P = 0.001) to that observed with either
factor alone.
Sensitivity analyses investigating the
associations with higher levels of CAC
showed similar point estimates but wider
conﬁdence intervals as a consequence of
there being only 451 people with CAC
.20 and 171 people with CAC.100 (for
CAC .20: OR 1.221 [95% CI 0.955–
1.560] for NAFLD and 1.094 (0.994–
1.204) for IR; for CAC.100: 1.114
[0.751–1.651] for NAFLD and 1.201
[1.062–1.357] for IR).
CONCLUSIONSdOur results show
for the ﬁrst time that fatty liver, IR, and
diabetes were all associated with a CAC
score .0, independently of each other
and MetS components. These results
also show, importantly, that combining
fatty liver and IR was not associated
with a marked increase in OR for the
association of both risk factors together
with CAC .0 score. In contrast, we
have shown in this cohort that combining
fatty liver and IR was associated with a
considerable increase in the OR for inci-
dent diabetes (20), suggesting that the
relationship between fatty liver, IR, and
diabetes is different from the relationship
between fatty liver, IR, and CAC score as a
marker of early atherosclerosis.
Our novel data were obtained from
the retrospective analysis of data from a
relatively healthy, young, occupational
cohort, and the association between both
fatty liver and HOMA-IR as a continuous
variable (or IR as a categorical variable) and
CAC score .0 persisted after adjustment
for features ofMetS and pre-existing vascu-
lar disease. These data show that the asso-
ciation between both fatty liver and
Table 1dCharacteristics of 10,153 individuals according to CAC score = 0 and
CAC score >0
CAC = 0 CAC .0 P
n 9,238 915
Age (years) 41.21 6 6.55 48.98 6 9.05 ,0.001
Sex ,0.001
Male 6,943 (75.2%) 802 (87.7%)
Female 2,295 (24.8%) 113 (12.3%)
Triglyceride (mmol/L) median
[IQR] 1.22 [0.86–1.75] 1.46 [1.02–2.07] ,0.001
HDL-C (mmol/L) 1.38 6 0.34 1.28 6 0.31 ,0.001
LDL-C (mmol/L) 3.23 6 0.83 3.49 6 0.91 ,0.001
BMI (kg/m2) 24.1 6 3.16 25.0 6 3.06 ,0.001
Waist (cm) 83.7 6 8.43 86.3 6 7.90 ,0.001
Glucose (mmol/L) 5.28 6 0.81 5.57 6 1.25 ,0.001
Systolic blood pressure (mmHg) 115.8 6 12.3 120.1 6 12.5 ,0.001
Diastolic blood pressure (mmHg) 73.6 6 8.93 77.0 6 8.97 ,0.001
HOMA-IR 1.39 6 0.99 1.65 6 1.28 ,0.001
ALT (units/L) 26.7 6 20.2 31.7 6 21.7 ,0.001
AST (units/L) 23.2 6 10.3 26.8 6 14.0 ,0.001
gGT (units/L) 33.1 6 33.7 50.0 6 32.8 ,0.001
Hx CVA 15 (0.2%) 10 (1.1%) ,0.001
Hx CHD 42 (0.5%) 37 (4.0%) ,0.001
Hx HTN 800 (8.7%) 269 (29.4%) ,0.001
Hx DM 238 (2.6%) 118 (12.9%) ,0.001
Smoking ,0.001
Nonsmoker 5,406 (58.5%) 388 (42.4%)
Ex-smoker 2,266 (24.5%) 328 (35.8%)
Current smoker 1,566 (17.0%) 199 (21.7%)
Alcohol (g/day) 5.63 6 6.09 6.17 6 6.24 0.01
Activity ($30 min per day,
number of days per week) 0.002
No 4,375 (47.4%) 388 (42.4%)
1 day 1,919 (20.8%) 175 (19.1%)
2 days 1,299 (14.1%) 150 (16.4%)
$3 days 1,645 (17.7%) 202 (22.1%)
Large waist (cm); M $90, F $80 2,644 (28.8%) 326 (35.6%) ,0.001
MetS 1,055 (16.3%) 264 (28.9%) ,0.001
Fatty liver (%) 3,274 (40.3%) 510 (55.7%) ,0.001
Insulin resistant (%) 2,230 (24.1%) 308 (33.7%) ,0.001
IR = HOMA-IR $1.75 (top quartile). Hypertension (HTN) was deﬁned by systolic blood pressure $140,
diastolic blood pressure $90, or medication for HTN. ALT, alanine aminotransferase; AST, aspartate ami-
notransferase; gGT, g glutamyl transferase; DM, diabetes mellitus; Hx, prior history.
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HOMA-IR (or IR) and a CAC score.0 was
independent of the presence of diabetes,
emphasizing that diabetes is unlikely to
mediate any relationship between NAFLD,
or IR, and atherosclerosis. Sensitivity anal-
yses investigating the associations with
higher levels of CAC showed similar point
estimates. Coefﬁcients of variation for mea-
surement of fatty liver and CAC within this
cohort are not available, and it is possible
that random misclassiﬁcation bias may
have underestimated the strength of the
association.
To date, there are no similar studies
that have investigated relationships
between a marker of early development
of coronary artery atherosclerosis and
fatty liver, IR, and MetS features in large,
predominantly healthy, middle-aged
cohorts. Some previous studies have
shown associations between increases in
liver enzymes and the presence of CAC
(25), or between liver fat, measured by
ultrasound or CT, and CAC (26–28). In
contrast, other investigators have failed to
ﬁnd independent associations between
measures of liver fat and CAC (29,30).
This study extends previous work by in-
cluding people without diabetes and in-
cluding assessment of the effects of both
IR and fatty liver as a marker of NAFLD.
The strong associations between
NAFLD and multiple complex metabolic
and proinﬂammatory changes that have
an effect on the vasculature (13,14) mean
that it is very difﬁcult to identify causality
in assessing the relationship between
NAFLD, IR, and CVD. It is plausible
that a predisposition toward NAFLD
could reﬂect the presence of particularly
marked IR and that the development and
progression of the liver disease per se
(with increasing inﬂammation and ﬁbro-
sis) could further worsen IR and thereby
increase CVD risk. Some of the discrepant
results between studies investigating rela-
tionships betweenNAFLD and CAC score
could reﬂect varying severity of NAFLD
both between subjects within studies
and between studies. Nonalcoholic
steatohepatitis (NASH) is a more severe
form of NAFLD, and NASH is more
strongly associated with CVD and IR
than simple steatosis (10,16). The hepatic
inﬂammation that occurs with NASH is
marked by macrophage activation (31),
and it is possible that vascular inﬂamma-
tion is also more marked with NASH (and
increased IR), compared with simple
steatosis. Consequently, it seems likely
that altered liver fat metabolism, insulin
sensitivity, and some component of the
inﬂammatory process are the critical fac-
tors contributing to vascular disease in
NAFLD (14). Thus, when considering
the strength of the relationship between
NAFLD and risk of CVD in individual
patients, we suggest that the clinician
needs to consider not just the severity of
the liver disease but also markers of IR
and inﬂammation.
There are a few limitations to our
study. Fatty liver was assessed by liver
ultrasound, and ultrasonography has lim-
ited sensitivity, being unable to detect
liver fat inﬁltration that is ,30% by liver
weight. Ultrasonography was performed
by experienced clinical radiologists who
diagnosed fatty liver based on known
standard clinical criteria that included
hepatorenal echo contrast, liver bright-
ness, and vascular blurring. We are there-
fore unable to include evidence of
agreement between radiologists. How-
ever, in the presented analyses, we used
the clinical deﬁnition of fatty liver as a di-
chotomous exposure variable. It is un-
likely that fatty liver status would have
been inﬂuenced by CAC score, and con-
sequently any random misclassiﬁcation
bias of fatty liver status would bias our
ﬁnding (showing the association between
fatty liver and CAC score.0) toward the
null. Although magnetic resonance spec-
troscopy may detect as little as 5% liver
fat, undertaking this diagnostic test was
not feasible in our large cohort. We are
also unable to comment on NAFLD sever-
ity in this study because liver biopsy and
histological assessment using the Kleiner
score (32), which is the gold standard for
assessing hepatic inﬂammation and ﬁbro-
sis, were not performed. Consequently, we
are unable to examine whether the more
severe forms of NAFLD, such as NASH
with ﬁbrosis, are associated with higher
CAC scores. There is no established deﬁni-
tion of IR as a categorical variable, and the
use of a particular centile or value deﬁned
from receiver operating curves provides an
arbitrary, population-speciﬁc cut point.
The validity of the cut point used for these
analyses could be explored in other popu-
lations. Additionally, our study is limited to
Table 2dAssociations between fatty liver, cardiometabolic risk factors, and CAC score
>0; derived from a multivariable logistic regression model containing all variables
Model dependent variable
Coronary artery calcium score .0 ORs 95% CIs P value
Age (per year) 1.13 1.12–1.14 ,0.001
Female sex 0.35 0.27–0.47 ,0.001
Triglyceride (per mg/dL) 1.03 0.95–1.11 0.51
HDL-C (per mg/dL) 0.71 0.53–0.95 0.02
LDL-C (per mg/dL) 1.44 1.31–1.57 ,0.001
Waist (per cm) 0.99 0.98–1.00 0.06
Fatty liver 1.21 1.01–1.45 0.04
Systolic blood pressure (per mmHg) 1.01 1.00–1.02 0.02
Alcohol (per unit) 1.00 0.99–1.02 0.75
Smoking (ex/current vs. never) 1.35 1.14–1.60 ,0.001
Activity (30 min/day vs. no activity) 1.14 0.98–1.33 0.08
Hx CVA 3.56 1.39–9.12 0.01
Hx CHD 2.72 1.56–4.75 0.001
Hx HTN 2.21 1.82–2.68 ,0.001
Hx diabetes 2.34 1.77–3.10 ,0.001
HOMA-IR (per 1.0 unit) 1.10 1.02–1.18 0.02
Hypertension (HTN) was deﬁned by systolic blood pressure $140, diastolic blood pressure $90, or med-
ication for HTN. Hx, prior history.
Table 3dNumber and percentage of subjects with a CAC score >0% according to the
presence of fatty liver and/or IR
No fatty liver
and no IR Fatty liver only IR only Fatty liver and IR All groups combined
CAC .0, n(%) 339 (6.5) 268 (11.3) 66 (9.9) 242 (12.9) 915 (9.0)
Total subjects 5,250 2,365 669 1,869 10,153
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one ethnic group, and the distribution of
risk factors and the association between
NAFLD and CAC may differ by ethnic
group.
In conclusion, we have shown that
both fatty liver and IR (measured by con-
tinuous or categorical variables) are inde-
pendently associated with the presence of
CAC, a marker of preclinical atheroscle-
rosis. These associations are independent
of diabetes, MetS features, other conven-
tional cardiovascular risk factors, and
pre-existing CVD.
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